1. Academic Validation
  2. Discovery and Optimization of LATS1 and LATS2 Kinase Inhibitors for Use in Regenerative Medicine

Discovery and Optimization of LATS1 and LATS2 Kinase Inhibitors for Use in Regenerative Medicine

  • J Med Chem. 2025 Aug 28;68(16):17499-17515. doi: 10.1021/acs.jmedchem.5c01027.
Patrick J Morris 1 Damien Y Duveau 1 Michele Ceribelli 1 Frances Anne Tosto 1 Dara N Love 1 Bridget S Scherer 1 Dingyin Tao 1 Yuhong Fang 1 Lale Evsen 1 Samuel A Kotler 1 Christopher A LeClair 1 Ganesha Rai 1 Craig J Thomas 1 Scott B Hoyt 1
Affiliations

Affiliation

  • 1 Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland 20850, United States.
Abstract

The Large Tumor Suppressor Kinases 1 and 2 (LATS1/2) are serine/threonine kinases that play an essential role in Hippo pathway activation and influence multiple physiological events ranging from organ growth to tissue regeneration. As a result, pharmacological inhibition of LATS1/2 represents a promising strategy for therapeutic intervention in multiple indications. Within, we present the discovery of potent and selective inhibitors of the kinases LATS1 and LATS2. Using a scaffold hopping strategy from the reported Akt Inhibitor AT-7867 (1) we pursued a series of structure activity relationship (SAR) studies that dramatically improved potency versus LATS1 and LATS2, while concurrently improving kinome-wide selectivity. ADME properties were further optimized via introduction of conformational restriction into the target molecule, to lead to compound 27 which possesses potent inhibitory activity against both LATS1 and LATS2 and proof of concept activity in wound healing models.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-175649
    LATS1/2抑制剂
    YAP